China and Hong Kong based Qiming Venture Partners has led a $20 million series A round in Connect Biopharmaceuticals Ltd, a company developing immune modulators for treating conditions like autoimmune diseases and cancer, according to the company announcement on January 25.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
